The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L04 | Immunosuppressants | |
| 3 | L04A | Immunosuppressants | |
| 4 | L04AE | Sphingosine-1-phosphate (S1P) receptor modulators | |
| 5 | L04AE02 |
| Active Ingredient | Description | |
|---|---|---|
| Ozanimod |
Ozanimod is a sphingosine 1-phosphate (S1P) receptor modulator, which binds selectively to sphingosine 1-phosphate receptor subtypes 1 and 5. Ozanimod causes lymphocyte retention in lymphoid tissues. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ZEPOSIA Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| ZEPOSIA Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
